United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Revenue of United Therapeutics Corporation (UTHR)
Revenue in 2023 (TTM): $2.33 B
According to United Therapeutics Corporation's latest financial reports the company's current revenue (TTM) is $2.33 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of United Therapeutics Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.33 B | $2.07 B | $1.39 B | $1.27 B | $984.8 M |
| 2022 | $1.94 B | $1.79 B | $1.04 B | $950.6 M | $727.3 M |
| 2021 | $1.69 B | $1.56 B | $736.8 M | $593.9 M | $475.8 M |
| 2020 | $1.48 B | $1.38 B | $646.3 M | $638.9 M | $514.8 M |
| 2019 | $1.45 B | $1.33 B | $-74,899,999 | $-165,000,000 | $-104,500,000 |
| 2018 | $1.63 B | $1.43 B | $838.4 M | $758.9 M | $589.2 M |
| 2017 | $1.73 B | $1.62 B | $1.05 B | $769.5 M | $417.9 M |
| 2016 | $1.6 B | $1.53 B | $1.09 B | $1.06 B | $713.7 M |
| 2015 | $1.47 B | $1.4 B | $1.08 B | $1.04 B | $651.64 M |
| 2014 | $1.29 B | $1.16 B | $575.02 M | $525.18 M | $340.07 M |
| 2013 | $1.12 B | $985.86 M | $323.76 M | $278.9 M | $174.56 M |
| 2012 | $916.08 M | $796.78 M | $484.46 M | $440.67 M | $304.44 M |
| 2011 | $743.18 M | $654.28 M | $341.02 M | $299.12 M | $217.87 M |
| 2010 | $603.83 M | $530.37 M | $185.47 M | $147.84 M | $105.92 M |
| 2009 | $369.85 M | $324.53 M | $43.04 M | $18.77 M | $19.46 M |
| 2008 | $281.5 M | $251.43 M | $-67,746,000 | $-72,298,000 | $-42,789,000 |
| 2007 | $210.94 M | $188.68 M | $22.19 M | $16.58 M | $19.86 M |
| 2006 | $159.63 M | $142.6 M | $28.98 M | $39.91 M | $73.97 M |
| 2005 | $115.92 M | $103.6 M | $50.09 M | $47.52 M | $65.02 M |
| 2004 | $73.59 M | $65.34 M | $17.83 M | $15.45 M | $15.45 M |
| 2003 | $53.34 M | $46.56 M | $-9,201,000 | $-9,969,000 | $-9,969,000 |
| 2002 | $30.12 M | $24.66 M | $-14,868,000 | $-23,651,000 | $-23,651,000 |
| 2001 | $5.73 M | $2.59 M | $-43,424,000 | $-37,287,749 | $-37,287,749 |
| 2000 | $2.05 M | $343.47 K | $-81,580,421 | $-86,181,694 | $-75,608,490 |
| 1999 | $400 K | $-1,000,000 | $-36,663,500 | $-35,300,000 | $-33,500,000 |
| 1998 | $100 K | $100 K | $-13,800,000 | $-12,800,000 | $-12,800,000 |